Drugs / NK-92 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00990717 | Mar 2005 → Jul 2012 | Hodgkins lymphoma, leukemia, plasma cell myeloma | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK-92 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990717 ↗ |
| Modality | Cell therapy | “The infusion of an irradiated NK cell line is appealing as it is a source of cells that can be expanded to therapeutic quantities” NCT00990717 ↗ |
| Route | Intravenous | “Cells are administered as an intravenous infusion over one hour” NCT00990717 ↗ |